Oxford Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Oxford Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-102,631	Closed	-$901K	–	1142
2019 Q4	$901K	Sell	102,631 -5,945	-5%	-$43.7K	0.03%	927
2019 Q3	$811K	Buy	108,576 +50,191	+86%	+$457K	0.02%	1041
2019 Q2	$544K	Sell	58,385 -78,038	-57%	-$569K	0.01%	1243
2019 Q1	$716K	Buy	136,423 +45,084	+49%	+$257K	0.02%	1081
2018 Q4	$406K	Buy	+91,339	New	+$501K	0.01%	1278
2018 Q3	–	Sell	-50,332	Closed	-$349K	–	1903
2018 Q2	$349K	Sell	50,332 -72,235	-59%	-$709K	0.01%	1454
2018 Q1	$1.74M	Sell	122,567 -12,566	-9%	-$133K	0.04%	650
2017 Q4	$1.17M	Buy	135,133 +86,691	+179%	+$858K	0.03%	854
2017 Q3	$574K	Buy	48,442 +20,753	+75%	+$254K	0.01%	1149
2017 Q2	$387K	Buy	+27,689	New	+$317K	0.01%	1178

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Oxford Asset Management's SNDX Position: Q1 2020 in Review

Oxford Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2020, closing a stake of 102,631 shares — an estimated $901K sold.

Oxford Asset Management first reported a position in SNDX in Q2 2017 and held it in 10 quarters. The position peaked at $1.74M in Q1 2018. 83 funds tracked by Wall St. Rank hold SNDX as of Q1 2020.

Oxford Asset Management reported no remaining Syndax Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 102,631 Syndax Pharmaceuticals shares in Q1 2020, an estimated $901K.
Oxford Asset Management first reported a position in Syndax Pharmaceuticals in Q2 2017 and held it in 10 quarters.
Oxford Asset Management's Syndax Pharmaceuticals position peaked at $1.74M in Q1 2018.
83 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.